2020
Neurological safety of oxaliplatin in patients with uncommon variants in Charcot-Marie-tooth disease genes
Le-Rademacher J, Lopez C, Kanwar R, Major-Elechi B, Abyzov A, Banck M, Therneau T, Sloan J, Loprinzi C, Beutler A. Neurological safety of oxaliplatin in patients with uncommon variants in Charcot-Marie-tooth disease genes. Journal Of The Neurological Sciences 2020, 411: 116687. PMID: 32018185, PMCID: PMC7096263, DOI: 10.1016/j.jns.2020.116687.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyRisk of CIPNTooth disease (CMT) genesCIPN riskCharcot-MariePatient-reported outcome instrumentsSingle nucleotide variantsFavor of casesNeurological safetyCommon genetic testsNeurotoxic chemotherapyOxaliplatin therapyPeripheral neuropathyChemotherapy decisionsClinical guidanceOutcome instrumentsUncommon variantPatientsNon-synonymous single nucleotide variantsSignificant associationOxaliplatinGenetic testsRiskCommon single nucleotide variantsCMT
2017
Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials
Le-Rademacher J, Kanwar R, Seisler D, Pachman D, Qin R, Abyzov A, Ruddy K, Banck M, Lavoie Smith E, Dorsey S, Aaronson N, Sloan J, Loprinzi C, Beutler A. Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials. Supportive Care In Cancer 2017, 25: 3537-3544. PMID: 28634656, PMCID: PMC5693734, DOI: 10.1007/s00520-017-3780-y.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyCTCAE gradePatient-reported outcomesQLQ-CIPN20Peripheral neuropathyClinical trialsNCI Common Terminology CriteriaCommon Terminology CriteriaMultivariable linear mixed modelsRecent clinical trialsTerminology CriteriaAdverse eventsCancer QualityClinical caveatsSerial assessmentClinical trial datasetPractice guidelinesIndividual patientsEuropean OrganizationCTCAEPatientsOutcome variablesStrong positive associationLinear mixed modelsNeuropathy
2016
Testing of candidate single nucleotide variants associated with paclitaxel neuropathy in the trial NCCTG N08C1 (Alliance)
Boora G, Kanwar R, Kulkarni A, Abyzov A, Sloan J, Ruddy K, Banck M, Loprinzi C, Beutler A. Testing of candidate single nucleotide variants associated with paclitaxel neuropathy in the trial NCCTG N08C1 (Alliance). Cancer Medicine 2016, 5: 631-639. PMID: 26763541, PMCID: PMC4831281, DOI: 10.1002/cam4.625.Peer-Reviewed Original ResearchConceptsPaclitaxel-induced peripheral neuropathyProtective effectAdditional clinical cohortsSingle nucleotide variantsPrevious reportsGene CYP2C8Pharmacogenomic basisPeripheral neuropathyClinical parametersOdds ratioClinical cohortNucleotide variantsCandidate single nucleotide variantsMultiple studiesHigher likelihoodTaqMan PCRCYP2C8AssociationSequencing analysisRisk effectsSubset of findingsReportNeuropathyPrevious studiesPatients